Recce Pharmaceuticals

Recce Pharmaceuticals Debt / Assets

The Debt-to-Assets Ratio of Recce Pharmaceuticals (RCE.AX) as of Nov 22, 2026 is 1.22. In the previous year, Debt-to-Assets Ratio was 0.87 — a change of 41.15% (higher).

Debt / Assets

1.22

YoY

41.15%

Last updated:

Debt-to-Assets Ratio of Recce Pharmaceuticals is 2026 1.22 . Debt-to-Assets Ratio of Recce Pharmaceuticals was 2025 0.87 . It decreases by 41.15% higher compared to the previous year.

The Recce Pharmaceuticals Debt / Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Debt / Assets
Date
Debt / Assets
Jan 1, 2019
0.80 AUD
Jan 1, 2020
0.03 AUD
Jan 1, 2021
0.01 AUD
Jan 1, 2022
0.01 AUD
Jan 1, 2023
0.10 AUD
Jan 1, 2024
0.13 AUD
Jan 1, 2025
0.87 AUD
Jan 1, 2026
1.22 AUD
The Recce Pharmaceuticals Debt / Assets history
YEARDebt / AssetsYoY
1.22+41.15%
0.87+581.09%
0.13+29.90%
0.10+1,555.34%
0.01+1.15%
0.01-77.18%
0.03-96.79%
0.80+31,889.12%
0.00-98.87%
0.22+11,643.84%
0.00—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Recce Pharmaceuticals Stock analysis

What does Recce Pharmaceuticals do? Recce Pharmaceuticals Ltd. develops pharmaceutical drugs targeting germ-killing therapies, focusing on anti-infective solutions. The company’s pipeline includes RECCE 327, an intravenous and topical therapy for serious bacterial infections including superbugs, RECCE 435 as an oral treatment for bacterial infections, and RECCE 529 for viral infections. All compounds are 100% water soluble across all pH levels in liquid form, leveraging multi-layered mechanisms to combat bacterial and viral mutations. The company operates through research and development, with no additional product lines or services mentioned. Recce Pharmaceuticals Ltd. generates revenue primarily through the development and potential commercialization of its anti-infective drugs. The target market includes healthcare providers and institutions treating serious infections, particularly those dealing with antibiotic-resistant bacteria and viral pathogens. The company’s focus on broad-spectrum synthetic polymer anti-infectives positions it for partnerships with pharmaceutical distributors and healthcare systems seeking novel treatments for life-threatening infections. The business model relies on the progression of its drug pipeline from research to clinical trials and eventual market entry. RECCE 327, RECCE 435, and RECCE 529 are the only products described, with no mention of licensing agreements, partnerships, or additional revenue streams beyond drug development and sales. The company’s financial success depends on the successful advancement of these compounds through regulatory approval processes. Recce Pharmaceuticals is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Recce Pharmaceuticals stock

Debt-to-Assets Ratio of Recce Pharmaceuticals is 1.22 in 2026.

Debt-to-Assets Ratio of Recce Pharmaceuticals changed from 0.87 to 1.22, representing a 41.15% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Debt-to-Assets Ratio Recce Pharmaceuticals since 2006 – with annual values, charts, and detailed analysis.

The Debt-to-Assets ratio measures what percentage of a company's assets are financed through debt. Higher ratios indicate greater financial risk.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Debt-to-Assets Ratio's Recce Pharmaceuticals with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Recce Pharmaceuticals

All Key Metrics — Recce Pharmaceuticals